scholarly journals Emerging applications of genome-editing technology to examine functionality of GWAS-associated variants for complex traits

2018 ◽  
Vol 50 (7) ◽  
pp. 510-522 ◽  
Author(s):  
Andrew J. P. Smith ◽  
Panos Deloukas ◽  
Patricia B. Munroe
Keyword(s):  
Genome Editing ◽  
Complex Traits ◽  
Association Studies ◽  
Causal Variant ◽  
Zinc Finger Nucleases ◽  
Strong Linkage Disequilibrium ◽  
Genome Wide Association Studies ◽  
Transcription Activator ◽  
Base Editing

Over the last decade, genome-wide association studies (GWAS) have propelled the discovery of thousands of loci associated with complex diseases. The focus is now turning toward the function of these association signals, determining the causal variant(s) among those in strong linkage disequilibrium, and identifying their underlying mechanisms, such as long-range gene regulation. Genome-editing techniques utilizing zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and clustered regularly-interspaced short palindromic repeats with Cas9 nuclease (CRISPR-Cas9) are becoming the tools of choice to establish functionality for these variants, due to the ability to assess effects of single variants in vivo. This review will discuss examples of how these technologies have begun to aid functional analysis of GWAS loci for complex traits such as cardiovascular disease, Type 2 diabetes, cancer, obesity, and autoimmune disease. We focus on analysis of variants occurring within noncoding genomic regions, as these comprise the majority of GWAS variants, providing the greatest challenges to determining functionality, and compare editing strategies that provide different levels of evidence for variant functionality. The review describes molecular insights into some of these potentially causal variants and how these may relate to the pathology of the trait and look toward future directions for these technologies in post-GWAS analysis, such as base-editing.

scholarly journals Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques

2021 ◽  
Vol 12 ◽  
Author(s):  
Martina Rauner ◽  
Ines Foessl ◽  
Melissa M. Formosa ◽  
Erika Kague ◽  
Vid Prijatelj ◽  
...  
Keyword(s):  
Resource Sharing ◽  
Complex Traits ◽  
Cellular Localization ◽  
Target Genes ◽  
Mission Statement ◽  
Association Studies ◽  
Repetitive Sequences ◽  
Genome Wide Association Studies ◽  
Causal Genes

The availability of large human datasets for genome-wide association studies (GWAS) and the advancement of sequencing technologies have boosted the identification of genetic variants in complex and rare diseases in the skeletal field. Yet, interpreting results from human association studies remains a challenge. To bridge the gap between genetic association and causality, a systematic functional investigation is necessary. Multiple unknowns exist for putative causal genes, including cellular localization of the molecular function. Intermediate traits (“endophenotypes”), e.g. molecular quantitative trait loci (molQTLs), are needed to identify mechanisms of underlying associations. Furthermore, index variants often reside in non-coding regions of the genome, therefore challenging for interpretation. Knowledge of non-coding variance (e.g. ncRNAs), repetitive sequences, and regulatory interactions between enhancers and their target genes is central for understanding causal genes in skeletal conditions. Animal models with deep skeletal phenotyping and cell culture models have already facilitated fine mapping of some association signals, elucidated gene mechanisms, and revealed disease-relevant biology. However, to accelerate research towards bridging the current gap between association and causality in skeletal diseases, alternative in vivo platforms need to be used and developed in parallel with the current -omics and traditional in vivo resources. Therefore, we argue that as a field we need to establish resource-sharing standards to collectively address complex research questions. These standards will promote data integration from various -omics technologies and functional dissection of human complex traits. In this mission statement, we review the current available resources and as a group propose a consensus to facilitate resource sharing using existing and future resources. Such coordination efforts will maximize the acquisition of knowledge from different approaches and thus reduce redundancy and duplication of resources. These measures will help to understand the pathogenesis of osteoporosis and other skeletal diseases towards defining new and more efficient therapeutic targets.

scholarly journals True causal effect size heterogeneity is not required to explain trans-ethnic differences in GWAS signals

2016 ◽  
Author(s):  
Daniela Zanetti ◽  
Michael E. Weale
Keyword(s):  
Ethnic Differences ◽  
Effect Size ◽  
Complex Traits ◽  
Causal Effect ◽  
Association Studies ◽  
African Ancestry ◽  
Causal Variant ◽  
Genome Wide Association Studies ◽  
Population Differences ◽  
Relative Risks

AbstractThrough genome-wide association studies (GWASs), researchers have identified hundreds of genetic variants associated with particular complex traits. Previous studies have compared the pattern of association signals across different populations in real data, and these have detected differences in the strength and sometimes even the direction of GWAS signals. These differences could be due to a combination of (1) lack of power (insufficient sample sizes); (2) minor allele frequency (MAF) differences (again affecting power); (3) linkage disequilibrium (LD) differences (affecting power to ‘tag’ the causal variant); and (4) true differences in causal variant effect sizes (defined by relative risks).In the present work, we sought to assess whether the first three of these reasons are sufficient on their own to explain the observed incidence of trans-ethnic differences in replications of GWAS signals, or whether the fourth reason is also required. We simulated case-control data of European, Asian and African ancestry, drawing on observed MAF and LD patterns seen in the 1000-Genomes reference dataset and assuming the true causal relative risks were the same in all three populations.We found that a combination of Euro-centric SNP selection and between-population differences in LD, accentuated by the lower SNP density typical of older GWAS panels, was sufficient to explain the rate of trans-ethnic differences previously reported, without the need to assume between-population differences in true causal SNP effect size. This suggests a cross-population consistency that has implications for our understanding of the interplay between genetics and environment in the aetiology of complex human diseases.

scholarly journals Open Targets Genetics: An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci

2020 ◽  
Author(s):  
Edward Mountjoy ◽  
Ellen M. Schmidt ◽  
Miguel Carmona ◽  
Gareth Peat ◽  
Alfredo Miranda ◽  
...  
Keyword(s):  
Complex Traits ◽  
Drug Targets ◽  
Association Studies ◽  
Single Gene ◽  
Cell Types ◽  
Causal Variant ◽  
Genome Wide Association Studies ◽  
Open Approach ◽  
Protein Coding ◽  
Causal Genes

AbstractGenome-wide association studies (GWAS) have identified many variants robustly associated with complex traits but identifying the gene(s) mediating such associations is a major challenge. Here we present an open resource that provides systematic fine-mapping and protein-coding gene prioritization across 133,441 published human GWAS loci. We integrate diverse data sources, including genetics (from GWAS Catalog and UK Biobank) as well as transcriptomic, proteomic and epigenomic data across many tissues and cell types. We also provide systematic disease-disease and disease-molecular trait colocalization results across 92 cell types and tissues and identify 729 loci fine-mapped to a single coding causal variant and colocalized with a single gene. We trained a machine learning model using the fine mapped genetics and functional genomics data using 445 gold standard curated GWAS loci to distinguish causal genes from background genes at the same loci, outperforming a naive distance based model. Genes prioritized by our model are enriched for known approved drug targets (OR = 8.1, 95% CI: [5.7, 11.5]). These results will be regularly updated and are publicly available through a web portal, Open Targets Genetics (OTG, http://genetics.opentargets.org), enabling users to easily prioritize genes at disease-associated loci and assess their potential as drug targets.

scholarly journals Effect sizes of causal variants for gene expression and complex traits differ between populations

2021 ◽  
Author(s):  
Roshni A. Patel ◽  
Shaila A. Musharoff ◽  
Jeffrey P. Spence ◽  
Harold Pimentel ◽  
Catherine Tcheandjieu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Complex Traits ◽  
Association Studies ◽  
Causal Variant ◽  
Effect Sizes ◽  
European Ancestry ◽  
Genome Wide Association Studies ◽  
Polygenic Scores ◽  
Causal Variants ◽  
Variant Effect

Despite the growing number of genome-wide association studies (GWAS) for complex traits, it remains unclear whether effect sizes of causal genetic variants differ between populations. In principle, effect sizes of causal variants could differ between populations due to gene-by-gene or gene-by-environment interactions. However, comparing causal variant effect sizes is challenging: it is difficult to know which variants are causal, and comparisons of variant effect sizes are confounded by differences in linkage disequilibrium (LD) structure between ancestries. Here, we develop a method to assess causal variant effect size differences that overcomes these limitations. Specifically, we leverage the fact that segments of European ancestry shared between European-American and admixed African-American individuals have similar LD structure, allowing for unbiased comparisons of variant effect sizes in European ancestry segments. We apply our method to two types of traits: gene expression and low-density lipoprotein cholesterol (LDL-C). We find that causal variant effect sizes for gene expression are significantly different between European-Americans and African-Americans; for LDL-C, we observe a similar point estimate although this is not significant, likely due to lower statistical power. Cross-population differences in variant effect sizes highlight the role of genetic interactions in trait architecture and will contribute to the poor portability of polygenic scores across populations, reinforcing the importance of conducting GWAS on individuals of diverse ancestries and environments.

scholarly journals Gene editing and CRISPR in the clinic: current and future perspectives

2020 ◽  
Vol 40 (4) ◽  
Author(s):  
Matthew P. Hirakawa ◽  
Raga Krishnakumar ◽  
Jerilyn A. Timlin ◽  
James P. Carney ◽  
Kimberly S. Butler
Keyword(s):  
Clinical Trials ◽  
Genome Editing ◽  
Dna Sequences ◽  
Gene Editing ◽  
Ex Vivo ◽  
Scientific Basis ◽  
Current Status ◽  
Zinc Finger Nucleases ◽  
Transcription Activator

Abstract Genome editing technologies, particularly those based on zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short palindromic repeat DNA sequences)/Cas9 are rapidly progressing into clinical trials. Most clinical use of CRISPR to date has focused on ex vivo gene editing of cells followed by their re-introduction back into the patient. The ex vivo editing approach is highly effective for many disease states, including cancers and sickle cell disease, but ideally genome editing would also be applied to diseases which require cell modification in vivo. However, in vivo use of CRISPR technologies can be confounded by problems such as off-target editing, inefficient or off-target delivery, and stimulation of counterproductive immune responses. Current research addressing these issues may provide new opportunities for use of CRISPR in the clinical space. In this review, we examine the current status and scientific basis of clinical trials featuring ZFNs, TALENs, and CRISPR-based genome editing, the known limitations of CRISPR use in humans, and the rapidly developing CRISPR engineering space that should lay the groundwork for further translation to clinical application.

scholarly journals CRISPR/Cas9 gene-editing strategies in cardiovascular cells

2019 ◽  
Vol 116 (5) ◽  
pp. 894-907 ◽  
Author(s):  
Eva Vermersch ◽  
Charlène Jouve ◽  
Jean-Sébastien Hulot
Keyword(s):  
Cardiovascular Diseases ◽  
Genome Editing ◽  
Zinc Finger Nucleases ◽  
Public Health Issue ◽  
Transcription Activator ◽  
Knock Out ◽  
Cardiovascular Cells ◽  
Induced Pluripotent

Abstract Cardiovascular diseases are among the main causes of morbidity and mortality in Western countries and considered as a leading public health issue. Therefore, there is a strong need for new disease models to support the development of novel therapeutics approaches. The successive improvement of genome editing tools with zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and more recently with clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) has enabled the generation of genetically modified cells and organisms with much greater efficiency and precision than before. The simplicity of CRISPR/Cas9 technology made it especially suited for different studies, both in vitro and in vivo, and has been used in multiple studies evaluating gene functions, disease modelling, transcriptional regulation, and testing of novel therapeutic approaches. Notably, with the parallel development of human induced pluripotent stem cells (hiPSCs), the generation of knock-out and knock-in human cell lines significantly increased our understanding of mutation impacts and physiopathological mechanisms within the cardiovascular domain. Here, we review the recent development of CRISPR–Cas9 genome editing, the alternative tools, the available strategies to conduct genome editing in cardiovascular cells with a focus on its use for correcting mutations in vitro and in vivo both in germ and somatic cells. We will also highlight that, despite its potential, CRISPR/Cas9 technology comes with important technical and ethical limitations. The development of CRISPR/Cas9 genome editing for cardiovascular diseases indeed requires to develop a specific strategy in order to optimize the design of the genome editing tools, the manipulation of DNA repair mechanisms, the packaging and delivery of the tools to the studied organism, and the assessment of their efficiency and safety.

scholarly journals Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases

2021 ◽  
Vol 22 (20) ◽  
pp. 10985
Author(s):  
Juliët Schreurs ◽  
Claudia Sacchetto ◽  
Robin M. W. Colpaert ◽  
Libero Vitiello ◽  
Alessandra Rampazzo ◽  
...  
Keyword(s):  
Genome Editing ◽  
Disease Modeling ◽  
Zinc Finger Nucleases ◽  
Cardiac Diseases ◽  
Transcription Activator ◽  
Base Editing ◽  
Epochal Change ◽  
Recent Developments ◽  
Dna Editing ◽  
First Time

In the past two decades, genome editing has proven its value as a powerful tool for modeling or even treating numerous diseases. After the development of protein-guided systems such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), which for the first time made DNA editing an actual possibility, the advent of RNA-guided techniques has brought about an epochal change. Based on a bacterial anti-phage system, the CRISPR/Cas9 approach has provided a flexible and adaptable DNA-editing system that has been able to overcome several limitations associated with earlier methods, rapidly becoming the most common tool for both disease modeling and therapeutic studies. More recently, two novel CRISPR/Cas9-derived tools, namely base editing and prime editing, have further widened the range and accuracy of achievable genomic modifications. This review aims to provide an overview of the most recent developments in the genome-editing field and their applications in biomedical research, with a particular focus on models for the study and treatment of cardiac diseases.

scholarly journals Improved methods for multi-trait fine mapping of pleiotropic risk loci

2016 ◽  
Author(s):  
Gleb Kichaev ◽  
Megan Roytman ◽  
Ruth Johnson ◽  
Eleazar Eskin ◽  
Sara Lindstroem ◽  
...  
Keyword(s):  
Fine Mapping ◽  
Complex Traits ◽  
Functional Annotation ◽  
Large Scale ◽  
Association Studies ◽  
Real Data ◽  
Causal Variant ◽  
Genome Wide Association Studies ◽  
Annotation Data ◽  
Association Data

AbstractGenome-wide association studies (GWAS) have identified thousands of regions in the genome that contain genetic variants that increase risk for complex traits and diseases. However, the variants uncovered in GWAS are typically not biologicaly causal, but rather, correlated to the true causal variant through linkage disequilibrium (LD). To discern the true causal variant(s), a variety of statistical fine-mapping methods have been proposed to prioritize variants for functional validation. In this work we introduce a new approach, fastPAINTOR, that leverages evidence across correlated traits, as well as functional annotation data, to improve fine-mapping accuracy at pleiotropic risk loci. To improve computational efficiency, we describe an new importance sampling scheme to perform model inference. First, we demonstrate in simulations that by leveraging functional annotation data, fastPAINTOR increases fine-mapping resolution relative to existing methods. Next, we show that jointly modeling pleiotropic risk regions improves fine-mapping resolution relative to standard single trait and pleiotropic fine mapping strategies. We report a reduction in the number of SNPs required for follow-up in order to capture 90% of the causal variants from 23 SNPs per locus using a single trait to 12 SNPs when fine-mapping two traits simultaneously. Finally, we analyze summary association data from a large-scale GWAS of lipids and show that these improvements are largely sustained in real data.

scholarly journals In Vivo Genome Editing as a Therapeutic Approach

2018 ◽  
Vol 19 (9) ◽  
pp. 2721 ◽  
Author(s):  
Beatrice Ho ◽  
Sharon Loh ◽  
Woon Chan ◽  
Boon Soh
Keyword(s):  
Genome Editing ◽  
Genome Engineering ◽  
Genetic Diseases ◽  
Gene Mutations ◽  
Genetic Mutation ◽  
Zinc Finger Nucleases ◽  
Transcription Activator ◽  
Therapeutic Benefits ◽  
A Genome

Genome editing has been well established as a genome engineering tool that enables researchers to establish causal linkages between genetic mutation and biological phenotypes, providing further understanding of the genetic manifestation of many debilitating diseases. More recently, the paradigm of genome editing technologies has evolved to include the correction of mutations that cause diseases via the use of nucleases such as zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and more recently, Cas9 nuclease. With the aim of reversing disease phenotypes, which arise from somatic gene mutations, current research focuses on the clinical translatability of correcting human genetic diseases in vivo, to provide long-term therapeutic benefits and potentially circumvent the limitations of in vivo cell replacement therapy. In this review, in addition to providing an overview of the various genome editing techniques available, we have also summarized several in vivo genome engineering strategies that have successfully demonstrated disease correction via in vivo genome editing. The various benefits and challenges faced in applying in vivo genome editing in humans will also be discussed.

scholarly journals CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications

2020 ◽  
Vol 21 (9) ◽  
pp. 3038 ◽  
Author(s):  
Xingbo Xu ◽  
Melanie S. Hulshoff ◽  
Xiaoying Tan ◽  
Michael Zeisberg ◽  
Elisabeth M. Zeisberg
Keyword(s):  
Transcriptional Activation ◽  
Gene Activation ◽  
Zinc Finger Nucleases ◽  
Homing Endonucleases ◽  
Transcription Activator ◽  
Base Editing ◽  
Advantages And Disadvantages ◽  
Associated Proteins

The field of genome editing started with the discovery of meganucleases (e.g., the LAGLIDADG family of homing endonucleases) in yeast. After the discovery of transcription activator-like effector nucleases and zinc finger nucleases, the recently discovered clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated proteins (Cas) system has opened a new window of applications in the field of gene editing. Here, we review different Cas proteins and their corresponding features including advantages and disadvantages, and we provide an overview of the different endonuclease-deficient Cas protein (dCas) derivatives. These dCas derivatives consist of an endonuclease-deficient Cas9 which can be fused to different effector domains to perform distinct in vitro applications such as tracking, transcriptional activation and repression, as well as base editing. Finally, we review the in vivo applications of these dCas derivatives and discuss their potential to perform gene activation and repression in vivo, as well as their potential future use in human therapy.

Sign in / Sign up

Export Citation Format

Share Document